Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p‐EGFR and p‐ERK. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.